HRMY vs IMVT Stock Comparison
HRMY currently leads IMVT in this stock comparison, with AIQ scores of 73 vs 52. The clearest difference is quality.
What is the main difference between HRMY and IMVT?
HRMY leads the current stock comparison as Harmony Biosciences Holdings, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Harmony Biosciences Holdings, Inc. vs Immunovant, Inc.
HRMY leads
HRMY leads by 21 AIQ points, primarily on Quality and Risk Resilience, but the lead has narrowed from 31 points over 30 sessions.
Stable: 3 of 4 evidence groups support HRMY, its lead is narrowing, and its signal state is cleanly positive.
Harmony Biosciences Holdings, Inc.
Immunovant, Inc.
The Algovestiq AIQ Score currently favors HRMY over IMVT, 73 versus 52 as of Nov 15, 2026. HRMY's advantage is driven primarily by stronger quality and risk resilience. HRMY also shows the weaker technical structure relative to its 50-day moving average. 3 of 4 covered evidence groups favor HRMY today, and the comparison is rated Stable on stability: the leader's advantage has been narrowing. HRMY lead: Weakening — the AIQ differential moved from 31 to 21 points over 30 sessions.
Compare Harmony Biosciences Holdings, Inc. and Immunovant, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare HRMY and IMVT against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality77 vs 42HRMY +35
- Risk Resilience63 vs 52HRMY +11
- Momentum66 vs 61HRMY +5
3 of 4 evidence groups favor HRMY. HRMY’s edge is concentrated in quality and risk resilience.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 3 active signals are unchanged.
Largest factor move: Momentum +3
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.60x)
HRMY's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — HRMY and IMVT both carry a full feed there.
The central trade-off
HRMY (Harmony Biosciences Holdings, Inc.): the stronger current systematic profile, led by quality and risk resilience.
IMVT (Immunovant, Inc.): the counter-case, on technicals — but at materially higher volatility, 72.6% against 46.4%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
HRMYHRMY on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
HRMYHRMY on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
HRMYHRMY on the Momentum factor, by 5 points.
Lower downside
HRMYHRMY on Risk Resilience, by 11 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | HRMY | IMVT | Note |
|---|---|---|---|
| Implied upside to target | +52.5% | — | Level |
| Target dispersion | +35% | — | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 12 | 17 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 4 covered evidence groups favor HRMY. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | HRMY | 73 vs 52 |
| Fundamentals | HRMYon balance | revenue growth 2.9% vs -100%; EPS growth -36.2% vs 37.3%; TTM ROE 4.5% vs -14.8%; gross margin 74% vs 100%; operating margin 22.2% vs -74.9% — HRMY takes 3 of 5 decided legs, not all of them |
| Valuation | Not covered | Not covered |
| Technicals | IMVT | Price vs 50-day -12.6% vs 4.7%; vs 200-day -2.4% vs 5.7% |
| Risk Resilience | HRMY | Risk Resilience 63 vs 52 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of HRMY and IMVT and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 21 points. (supports the conclusion holding)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on HRMY.
How the comparison changed
120 daily snapshots · May 27 – Nov 13HRMY lead: Weakening — the AIQ differential moved from 31 to 21 points over 30 sessions.
- Today
- HRMY +21
- 73 vs 52
- 7 sessions ago
- HRMY +27
- 76 vs 49
- 30 sessions ago
- HRMY +31
- 80 vs 49
- 90 sessions ago
- HRMY +8
- 74 vs 66
The lead changed hands 3 times in this window, most recently on Jul 14 when IMVT moved ahead of HRMY.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 0 bearish / 2 neutral
Only HRMY
- ADX Trend Strengthening — neutral, trend, medium horizon
4 bullish / 3 bearish / 1 neutral, conflicted
Only IMVT
- Beta Spike Warning — bearish, risk_regime, long horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.60x)
- RSI Bearish Divergence — bearish, momentum, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 2 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode.
IMVT is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.12%, AIQ 0 points).
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.48%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1IMVT closes the Quality gap — currently 35 points behind, the largest single contributor to HRMY's edge.
- 2IMVT's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3HRMY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4The narrowing continues — the lead has already given back 10 points over 30 sessions, and a further 21-point move would eliminate HRMY's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
HRMY leads on balance| Metric | HRMY | IMVT |
|---|---|---|
| Revenue growth (YoY) | 2.9% | -100% |
| EPS growth (YoY) | -36.2% | 37.3% |
| Gross margin | 74% | 100% |
| Operating margin | 22.2% | -74.9% |
| Return on equity (TTM) | 4.5% | -14.8% |
| Debt to equity | 0.14 | 0 |
Performance
IMVT leads 5 of 6 windows| Metric | HRMY | IMVT |
|---|---|---|
| 1 week (5 sessions) | 2% | 12% |
| 1 month (20 sessions) | -11% | 27.9% |
| 3 months (63 sessions) | -11.5% | -21.8% |
| 6 months (126 sessions) | 12.2% | 24.3% |
| Year to date | -9.8% | 34.5% |
| 1 year (252 sessions) | 0.7% | 45.8% |
Technicals
IMVT has the stronger structure| Metric | HRMY | IMVT |
|---|---|---|
| RSI (14) | 36.4 | 58.1 |
| ADX (14) | 34.7 | 33.1 |
| Price vs 50-day | -12.6% | 4.7% |
| Price vs 200-day | -2.4% | 5.7% |
| Volatility (1M, annualized) | 46.4% | 72.6% |
Risk
HRMY is the more resilient| Metric | HRMY | IMVT |
|---|---|---|
| Beta | 0.63 | 1.58 |
| Sharpe ratio | 0.07 | 0.9 |
| Sortino ratio | 0.09 | 1.77 |
| Max drawdown | -34.5% | -40.5% |
| Current drawdown | -21.2% | -24% |
| Annualized volatility | 40.6% | 58.6% |
| Value at risk (95%) | -3.9% | -4.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, HRMY or IMVT?
On the Algovestiq AIQ Score, HRMY is the stronger of the two as of Nov 15, 2026, scoring 73 against IMVT's 52. The edge comes from quality and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is HRMY or IMVT the better buy right now?
HRMY carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 3 of 4 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor HRMY over IMVT?
The composite weights Quality, Value, Momentum and Risk Resilience. HRMY leads Quality by 35 points; HRMY leads Risk Resilience by 11 points; HRMY leads Momentum by 5 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, HRMY or IMVT?
Analyst price targets imply +52.5% upside for HRMY and not covered for IMVT. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, HRMY or IMVT?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, HRMY or IMVT?
HRMY on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, HRMY or IMVT?
HRMY on the Momentum factor, by 5 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, HRMY or IMVT?
HRMY is the more resilient of the two, so the other name carries the higher downside risk. HRMY on Risk Resilience, by 11 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is HRMY more profitable than IMVT?
The profitability evidence is mixed: gross margin 74% vs 100%; operating margin 22.2% vs -74.9%; ttm roe 4.5% vs -14.8%. HRMY leads on two measures and IMVT on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is HRMY's lead over IMVT getting stronger or weaker?
HRMY lead: Weakening — the AIQ differential moved from 31 to 21 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 3 times in that window, most recently on 2026-07-14, when IMVT moved ahead of HRMY.
What would change the HRMY vs IMVT verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: IMVT closes the Quality gap — currently 35 points behind, the largest single contributor to HRMY's edge; IMVT's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; HRMY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; the narrowing continues — the lead has already given back 10 points over 30 sessions, and a further 21-point move would eliminate HRMY's advantage entirely.
What do the current signals say about HRMY and IMVT?
HRMY: 1 bullish / 0 bearish / 2 neutral. IMVT: 4 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on HRMY is Golden Cross Active (bullish, long horizon). On IMVT it is Golden Cross Active (bullish, long horizon).
Compare HRMY and IMVT with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.